EpiFinder, Inc. was named the winner of two Silver Stevie® Awards in the Tech Startup of the Year – Software category and Startup of the Year – Business Services Industries category in The 16th Annual American Business Awards® today.
The American Business Awards are the U.S.A.’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small.
Nicknamed the Stevies for the Greek word meaning “crowned,” the awards will be presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 11.
More than 3,700 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories, including Startup of the Year, Executive of the Year, Best New Product or Service of the Year, Marketing Campaign of the Year, Live Event of the Year, and App of the Year, among others. EpiFinder, Inc. was nominated in the Tech Startup of the Year- Software and Startup of the Year – Business Services Industries categories and won both.
EpiFinder has raised close to $1M in investments and grant funding from investors, Flinn Foundation, Arizona State University Foundation, among many others. They were one of the top six teams to win Epilepsy Foundation’s 2017 Shark Tank Competition; a recent Mayo Clinic study demonstrated their ability to accurately screen for epilepsy and published that study in a peer-reviewed journal.
“I couldn’t possibly be prouder of our multidisciplinary and diverse team,” says Neel Mehta, Co-Founder & Chief Strategy Officer. “We are dedicated to helping end misdiagnosis and improve the lives of those who have epilepsy by providing clinical decision support tool to healthcare professionals. And we want to congratulate our fellow Stevie Awards winners including WebPT, Digital Air Strike, and others.”
One of the judges remarked, “EpiFinder has significantly improved the accuracy of Epilepsy diagnosis. The success of the product should fuel additional funding needed to expand the product line and allow the company to pursue additional innovations in the medical diagnostic field. Impressive company!”
More than 200 professionals worldwide participated in the judging process to select this year’s Stevie Award winners.
“The nominations submitted for The 2018 American Business Awards were outstanding. The competition was intense, and those recognized as Stevie Award winners should be immensely proud of this accomplishment,” said Michael Gallagher, president and founder of the Stevie Awards.
About EpiFinder, Inc.
EpiFinder is a healthcare software solutions and a neuro-spectrum differentiation company. It empowers doctor-patient interaction and provides a robust proprietary platform. It encourages patients to take ownership of their health through a ‘patient portal’ and provides doctors with a ‘clinical decision support tool’ and enhances the communication through engagement and data analytics. EpiFinder’s mission is to improve workflow, empower the doctor-patient relationship, and enhance patient outcomes. EpiFinder is revolutionizing the care of all neurological disorders by combining cutting-edge scientific research with the latest innovations, creating a disruptive technology in healthcare. The company is making a difference by improving people’s lives globally, and they plan to expand to other rare or hard to diagnose neurological diseases by 2020. http://www.epifinder.com
About the Stevie Awards
Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
Sponsors of The 2018 American Business Awards include HCL America, John Hancock Financial Services, and SoftPro.
EpiFinder, Inc., is pleased to announce its proprietary clinical decision analytics software to improve epilepsy syndrome diagnosis and seizure event management at the point-of-care. The early-stage Arizona company provides intelligent analytics and support to doctors, neurologists and healthcare professionals (Nurse Practitioners, Physician Assistants, and more) to enhance the lives of patients with epilepsy.
EpiFinder aims to improve the doctor-patient relationship. First, it can improve communication by more efficiently collecting information from the patient. Then, the system organizes this information so that the doctor can better understand the patient’s perspective. It then maps this to the latest aggregate knowledge towards better interpretation, advanced, efficient treatment, and reduced cost.
Per the Institute of Medicine report ‘Epilepsy Across the Spectrum,’ epilepsy is a brain disease that manifests as seizure events. In the United States alone, epilepsy affects 3.2 million people with 150,000 new epilepsy cases ever year. Of these, as many as 40% of patients with epilepsy are misdiagnosed and suffer from uncontrolled seizures, which limits their independence at best and can result in death at worst. People often suffer for years before their epilepsy can be correctly identified and treated. The monetary cost of epilepsy misdiagnosis and mismanagement of healthcare is $12.5 billion annually.
Patients frequently complain that doctors do not listen to them, while doctors complain that there are too many obstacles that reduce their time with their patients. When a first responder currently encounters, someone is experiencing a seizure; they collect general medical information for referring the patient to another healthcare professional. This process is inefficient, with the patient having to tell the same story to multiple health professionals and redundantly taking the same diagnostic tests as a chain of referral after referrals. Ultimately, when the specialist – epileptologists who can make the diagnosis – is found, the information collected may or may not even be relevant to the doctor who will ultimately diagnose and manage the condition.
EpiFinder can improve the efficiency of this process by guiding the data collection of the first responder or primary care professional, standardizing data usability, screening the information with evidence-based, peer-reviewed research and data, providing a guided differential diagnosis of epilepsy syndromes through translational biomedical informatics technology, and then implementing it through personalized medicine. This provides the latest actionable knowledge for the doctor to decide whether to either keep and treat the patient themselves or to refer them to specialists while allowing the primary care physician the opportunity to retain their patients. When the referral is necessary, the information collected is relevant to the specialist. For the patient, this reduces redundancy and cuts down on the time that proper action can be taken to limit the seizures. This is a tool that will be a new class of product to better assess and triage the patient population in a clinical setting.
“By providing quicker and more accurate diagnoses for an epilepsy syndrome, EpiFinder reduces health care costs for hospitals, enables doctors to provide personalized medicine, and helps to improve the quality of life for their patients.” –Robert Yao, CEO of EpiFinder, Inc.
EpiFinder provides value to patients by providing them a time-independent platform that can collect all the information they wish to provide first, saving them money and endless frustration. An algorithm then analyzes this data and presented to the doctor within the context of the latest knowledge. The doctor is then freed to understand the patient better and empowered to make better decisions about identification and management of the condition.
EpiFinder co-founders believe they have developed a sustainable business model that will result in exponential growth because it relies on a robust AI for all complex disease. While their initial launch will focus on decision support for epilepsy, the company’s goal is to expand the system for other neurologic or psychiatric diseases and eventually to more complex, rare, or hard to diagnose conditions. By translating science to improve people’s health, the team at EpiFinder is working hard to turn the art of medicine into a science.
“At the heart of EpiFinder,” says Mehta, “are the people. They achieve excellence and create value within their chosen fields while working in a collaborative and supportive environment.”
EpiFinder’s award winning, multidisciplinary team includes Biomedical Informaticist and software developers with expertise in artificial intelligence, knowledge representation, machine learning, and statistics. The company’s leadership has received numerous recognitions, and together, they work in harmony to deliver a product that can change lives on a global scale.
“EpiFinder’s vision is to revolutionize the care of all neurological disorders by combining cutting edge scientific research with the latest technologies to the doctor-patient relationship”, said Neel Mehta, at the 14th conference on Anti-epileptic Drug and Device Trials, held every two years and sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania and the Epilepsy Foundation.
EpiFinder, Inc., a business analytics platform to simplify healthcare assessment and management through algorithmic methods, based in Scottsdale, Arizona, announces they are a:
Leader in determining the many differences in neurological conditions.
Pioneer in assessing epilepsy syndromes and aiding the doctor in determining the most effective course of treatment through advanced and personalized analysis of symptoms.
Product provider of easy to access clinical solutions and patient apps on iPhone and Android.
EpiFinder has the potential to improve health outcomes through their new Patient Portal App. It is designed to make the diagnosis and treatment of epilepsy easier and faster by solving the problems that lead to the misdiagnosis of the fourth most common neurological disease.
Patients are often stressed speaking with doctors and healthcare professionals due to time constraints to remember essential details in a sterile, time-pressured environment. The new Patient Portal App will empower the patient and their loved ones to open the App and record all of the details while it is fresh in their mind. It works by giving them the prompts and the time and space needed to tell their story fully.
The App then takes the information and summarizes it into standard medical terms familiar to healthcare professionals. This strengthens the doctor-patient relationship by encouraging understanding and discussion about the condition for both patients and clinical staff.
When necessary, the EpiFinder’s Patient Portal App will allow patients to be more quickly connected to the healthcare professional that will have the potential to address their specific epilepsy diagnosis and create an effective treatment plan. Healthcare professionals may then receive a summary of the patient’s epilepsy history and seizure experiences before the patient even arrives for their appointment, saving both time and money.
Ultimately, EpiFinder’s goal is to end misdiagnosis and improve the quality of life faster for those diagnosed with epilepsy through their Patient Portal App.
“Our vision is to improve patient outcomes by revolutionizing the care of seizures, epilepsy, and neurological conditions with our intelligent analytics technology that translates cutting-edge scientific research into clinical solutions.” – EpiFinder Co-Founder and Chief Strategy Officer, Neel Mehta.